FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

研究用のみ。 完全な免責事項 →

研究/Highlight the role of humanin and MOTS-c in aging processes and their potential as therapeutic targets for age-related diseases.
研究ライブラリに戻る
humaninMOTS-c

Highlight the role of humanin and MOTS-c in aging processes and their potential as therapeutic targets for age-related diseases.

May 17, 2026
Share

元の論文

Mitochondrial-derived peptides in aging and age-related diseases.

Kim Su-Jeong et al.GeroScience2021
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Mitochondrial Messengers: Humanin and MOTS-c in Aging and Disease

Published: May 17, 2026 | Source: GeroScience (2021) | Category: humanin, MOTS-c

Overview

A recent review published in GeroScience highlights the critical role of mitochondrial-derived peptides, specifically humanin and MOTS-c, in aging processes such as cellular senescence, chronic inflammation, and cognitive decline. This research suggests that these peptides may serve as potential therapeutic targets for age-related diseases.

Study Background

As we age, our mitochondria—the powerhouses within cells—become less efficient, leading to a range of health issues from muscle weakness to neurodegeneration. Previous studies have linked mitochondrial dysfunction with aging and age-related diseases, but the specific mechanisms remain unclear. The review by Kim et al. focuses on mitochondrial-derived peptides (MDPs) like humanin and MOTS-c, which are small molecules produced within mitochondria that play a role in cellular health.

What the Research Found

The study synthesizes existing literature to demonstrate how MDPs contribute to aging processes:

  • Humanin: This peptide is known for its anti-apoptotic (anti-cell death) properties and has been shown to protect cells from oxidative stress. It plays a significant role in reducing cellular senescence, which is the process by which cells lose their ability to divide.
  • MOTS-c: Another MDP, MOTS-c, regulates metabolism and inflammation. Studies have linked it with improved insulin sensitivity and reduced chronic inflammation, both of which are crucial for aging healthily.

The review also discusses genetic variations in humanin and MOTS-c that are associated with age-related diseases such as Alzheimer's disease and type 2 diabetes. These variations can affect the expression levels of MDPs, thereby influencing age-related phenotypes.

What This Means for Peptide Users

While this research highlights the potential therapeutic value of humanin and MOTS-c in combating aging processes, it is important to note that these peptides are still under investigation. For peptide users, understanding the role of MDPs can provide insights into how mitochondrial health impacts overall cellular function and longevity.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature rather than presenting new experimental data. This means it may not capture all recent findings or emerging research in the field. Additionally, while the potential therapeutic benefits of MDPs are promising, further clinical trials are necessary to confirm their efficacy and safety.

How This Compares to Previous Research

The review builds upon earlier studies that have individually examined humanin and MOTS-c but integrates them into a broader context of aging and age-related diseases. It aligns with other research suggesting the importance of mitochondrial health in cellular aging, yet it also highlights gaps in our understanding of how genetic variations influence MDP expression.

Our Analysis

PeptideVault's analysis suggests that while this review provides valuable insights into the role of humanin and MOTS-c in aging processes, more experimental data is needed to fully understand their therapeutic potential. The study effectively synthesizes existing knowledge but does not introduce new findings or methodologies.

Key Takeaways

  • Humanin and MOTS-c play crucial roles in protecting cells from damage and regulating metabolic health.
  • Genetic variations affect MDP levels, which can influence the development of age-related diseases.
  • Further research is needed to confirm the therapeutic potential of these peptides.

Original Source

Citation: Kim Su-Jeong, Miller Brendan, Kumagai Hiroshi et al. (2021). Mitochondrial-derived peptides in aging and age-related diseases.. GeroScience. DOI: 10.1007/s11357-020-00262-5

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。